The majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing draining lymphatics enhances anticancer immunity, resulting in dramatic response in HPV (Human Papilloma Virus) virus related cancers of the throat. This trial will leverage targeted tumor radiation and immunotherapy in advance of standard surgical therapy to improve the response of HPV (Human Papilloma Virus) throat cancer to radiation and immunotherapy.
This is a prospective, multi-center, open-label, one-arm, two-stage, Phase II study to evaluate the efficacy of neoadjuvant immunoradiotherapy (NIRT) in patients with stage I HPVOPC (Human Papilloma Virus Oropharynx Cancer) amenable to surgical resection, including AJCC (American Joint Committee on Cancer) VIII T1-2N1M0 HPVOPC (Human Papilloma Virus Oropharynx Cancer) and excluding patients with solitary lymph nodes less than 3 cm. A Simon's two-stage optimal design is used for this study. We will test the hypothesis that neoadjuvant stereotactic tumor targeting radiation along with CD47 inhibition (evorpacept) and PD-1 inhibition (pembrolizumab) provides pathologic response compared to current standard of care rates of locoregional control.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
28
After stereotactic radiation to primary tumor and neck on week 1 of study, Evorpacept 45 mg/kg is administered by IV infusion every three weeks starting on Week 2, Day 1 of study for a total two 21-day cycles (6 weeks)
UC San Diego Moores Cancer Center
La Jolla, California, United States
Providence Health & Services
Portland, Oregon, United States
Oregon Health and Science University
Portland, Oregon, United States
Pathologic complete response
Pathologic response is determined when surgery is performed at week 7-10 of study
Time frame: week 7-10
Major pathologic response
Major pathologic response is defined as \<10% viable tumor cells in the resection specimen) after surgical resection
Time frame: week 7-10
clinical response
clinical response will be determined by clinical and radiographic criteria by comparison of pretreatment and post-treatment assessment prior to surgery
Time frame: week 7
clinical to pathologic down-staging
clinical to pathologic down-staging will be assessed by comparing pretreatment AJCC (American Joint Committee on Cancer) VIII stage to pathologic stage determined by surgical pathology results. And decrease in overall Stage or decrease in T or N category will be defined as down staging.
Time frame: week 7-10
overall survival
survival will be determined based on intent to treat analysis at conclusion of study after 3 years
Time frame: 3 years
disease free survival
subjects will be assessed for presence of disease after completion of treatment and up to three years
Time frame: 3 years
Safety and toxicity
Safety and toxicity will be assessed by CTCAE for overall toxicity and safety and Clavien-Dindo for toxicity related to surgery.
Time frame: 11 months to three years
Patient-reported quality of life and functional outcomes (score 0-100 with 100 being best possible score)
The University of Washington-Quality of Life (UW-QOL) to assess standard penetration-aspiration score (PAS) will be used to assess patient and observer-reported quality of life and functional outcomes.
Time frame: post treatment at 7, 11 weeks and at 3 and 12 months
Patient-reported quality of life and functional outcomes (score 20-100 with 100 being best possible score)
MD Anderson Dysphagia Inventory (MDADI) to assess standard penetration-aspiration score (PAS) will be used to assess patient and observer-reported quality of life and functional outcomes.
Time frame: post treatment at 7, 11 weeks and at 3 and 12 months
Observer-reported quality of life and functional outcomes
Video Fluoroscopic Swallow Study (VFSS) to assess standard penetration-aspiration score (PAS) will be used to assess patient and observer-reported quality of life and functional outcomes.
Time frame: post treatment at 7, 11 weeks and at 3 and 12 months
Immune Correlates (T-cell infiltration)
Patients will undergo assessment of T-cell infiltration into primary tumors expressed as % staining in primary tumor sections on immunohistochemical staining.
Time frame: 7-11 weeks
Immune Correlates (shared tumor and sentinel node T-cell clones)
Patients will undergo assessment of frequency of shared tumor and sentinel node T-cell clones as defined by absolute number of shared clones,
Time frame: 7-11 weeks
Immune Correlates (B-cell germinal centers)
Patients will undergo assessment of number of B-cell germinal centers in draining sentinel lymph nodes compared to non-sentinel nodes as defined by average number of B-cell germinal centers per high powered field with random sampling of at least 10 high powered fields on microscopy.
Time frame: 7-11 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.